Effective characteristics and benefit population of Peiyuantongnao capsule for ischemic stroke: a multi-center registry study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900023273

Enrollment

Unknown

Registered

2019-05-20

Start date

2019-06-01

Completion date

Unknown

Last updated

2019-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

Case series: Peiyuantongnao capsule

Eligibility

Sex/Gender

All

Age

35 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Confirmed diagnosis of Meridian in ischemic stroke; 2. Aged 35 to 80 years; 3. The course of the disease is between 14 and 60 days after the onset 4. Patients were taking Peiyuantongnao capsule when included.

Exclusion criteria

Exclusion criteria: 1. Inability to cooperate with clinic follow-up due to serious condition; 2. With other diseases that affect the assessment of neurological function and ability in daily life; 3. Patients with obvious abnormal liver function when included; 4. Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
Degree of disability;	—

Secondary

Measure	Time frame
the degree of neurological impairment;Activities of daily living;cognitive function;emotional changes in patients;the benefit population;	—

Countries

China

Contacts

Public ContactGao Ying

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

gaoying973@126.com+86 10 84013209

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026